Identification of New Patient Stratification Tools in MSS RAS mt mCRC

Mechanistic and Molecular Study of the Process of Metastatic Dissemination in Colorectal Cancer

NCT03613194 ·Status: UNKNOWN ·Phase: NA

Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

NCT01910610 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

NCT04495621 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies

NCT03274882 ·Status: COMPLETED ·Phase: PHASE2

Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer

NCT00559676 ·Status: COMPLETED ·Phase: PHASE4

Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery

NCT00466505 ·Status: COMPLETED ·Phase: PHASE2

Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments

NCT00560560 ·Status: COMPLETED ·Phase: PHASE2

Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer

NCT01387880 ·Status: COMPLETED ·Phase: PHASE2

For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy

NCT00037180 ·Status: TERMINATED ·Phase: PHASE2

Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)

NCT00154102 ·Status: COMPLETED ·Phase: PHASE3

Study of Micrometastases in Patients With Stage I or Stage II Localized Colon Cancer That Can Be Removed by Surgery

NCT01097265 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

NCT01545141 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype

NCT01450319 ·Status: COMPLETED ·Phase: PHASE2

Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients

NCT01453257 ·Status: COMPLETED ·Phase: PHASE2

Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer

NCT04050345 ·Status: RECRUITING

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

NCT04607421 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma

NCT00362102 ·Status: COMPLETED ·Phase: PHASE2

Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)

NCT02404935 ·Status: COMPLETED ·Phase: PHASE2

Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer

NCT00551421 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy

NCT00852228 ·Status: UNKNOWN ·Phase: PHASE2

Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer

NCT01919879 ·Status: COMPLETED ·Phase: PHASE2

A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy

NCT02743221 ·Status: COMPLETED ·Phase: PHASE2

Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer

NCT06763029 ·Status: RECRUITING ·Phase: PHASE2

Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer

NCT05959356 ·Status: RECRUITING ·Phase: PHASE2

Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer

NCT03647839 ·Status: COMPLETED ·Phase: PHASE2